• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » SSRIs and Intracerebral Hemorrhage Risk

SSRIs and Intracerebral Hemorrhage Risk

May 21, 2021
Paul Barkopoulos, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Kubiszewski P et al, JAMA Neurol 2020;e203142. Epub ahead of print.

Depression after strokes is very common, affecting about 50% of stroke patients. Many such patients are treated with SSRIs, which are generally effective but potentially dangerous because they can increase the risk of bleeding due to impaired platelet aggregation. This is especially dangerous in intracerebral hemorrhages (ICHs), which cause half of stroke mortality even though they represent only 10–15% of strokes. A recent study examined the safety of SSRIs in patients who recently had an ICH.

In this longitudinal study, researchers recruited a total of 1,279 patients who were treated for ICH at a single academic hospital from January 2006 to December 2017. Of these patients, 766 were diagnosed with depression and 281 were started on SSRIs. Patients receiving SSRIs were divided into two categories: high or low risk for a recurrent stroke. High risk criteria included: 1) a prior history of any type of stroke; 2) presence of apolipoprotein E2/E4 gene variants; 3) Black or Hispanic race; and 4) lobar ICH, as opposed to deeper tissues such as the basal ganglia, brainstem, and cerebellum.

SSRI use was associated with higher ICH recurrence (hazard ratio [HR] 1.3). 6.1% of high-risk patients on SSRIs had a recurrent ICH vs only 3.8% of those not on SSRIs. In contrast, low-risk patients on SSRIs were not at greater risk for a recurrence than those not on SSRIs (2.9% vs 2.3%). On the positive side, SSRIs were effective at resolving post-stroke depression, with patients on the meds 1.5 times more likely to experience remission. Low doses of SSRIs (< 50% maximum recommended dose) were just as effective as high doses (> 50% maximum recommended dose) and were associated with a lower risk of ICH recurrence (HR 1.25 and 1.61 respectively).

CHPR’s Take
SSRIs are effective in treating post-ICH depression, but for patients at high risk for another stroke, the mood benefits may not be worth the higher risk of having another ICH. A good tip from this study is to keep SSRI dosing low to avoid heightening the risk for stroke ­recurrence.
Hospital Psychiatry
KEYWORDS bleeding citalopram depression escitalopram fluoxetine geriatric hemorrhagic intra-cerebral-hemorrhage mortality paroxetine post-stroke-depression prozac serotonin-specific-reuptake-inhibitors-ssris sertraline ssris stroke
Paul Barkopoulos, MD.

QT Intervals in Psychiatric Practice

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
Finally, Effective Treatments for Tardive Dyskinesia
Decisional Capacity
Capacity Assessment in Pregnant Patients
Suvorexant May Prevent Delirium in Hospitalized Patients
SSRIs and Intracerebral Hemorrhage Risk
Can Antidepressants Prolong Survival in Cancer Patients?
Hyperprolactinemia: Effective Treatment With Aripiprazole
Note From the Editor-in-Chief
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.